Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Sarcoma × trametinib × Clear all

Phase

Status

Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 11 Multiple Myeloma 5 Carcinoma, Non-Small-Cell Lung 5 Neurofibromatosis 1 4 Neoplasm Metastasis 4 Lymphoma 4 Hematologic Neoplasms 4 Glioma 4 Thyroid Neoplasms 3 Thyroid Carcinoma, Anaplastic 3 Neurofibroma, Plexiform 3 Colorectal Neoplasms 3 Brain Neoplasms 3 Pancreatic Neoplasms 2 Glioblastoma 2 Astrocytoma 2 Uveal Melanoma 1 Thyroid cancer, follicular 1 Thyroid cancer, Hurthle cell 1 Thyroid Cancer, Papillary 1 Solid Tumors, KRAS Mutation; SOS1 1 Sarcoma 1 Prostatic Neoplasms 1 Oligodendroglioma 1 Neurocytoma 1 Neuroblastoma 1 Lung Neoplasms 1 Leukemia, Myelomonocytic, Juvenile 1 Histiocytosis, Langerhans-Cell 1 Ganglioneuroma 1

Interventions

Nivolumab 10 pembrolizumab 9 Radiotherapy 9 Magnetic Resonance Spectroscopy 9 Specimen Handling 8 Doxorubicin 8 Cyclophosphamide 7 Biopsy 7 X-Rays 6 Ipilimumab 6 Phantoms, Imaging 5 talimogene laherparepvec 4 Radiation 4 Nuclear Medicine Department, Hospital 4 selpercatinib 3 pazopanib 3 palbociclib 3 cabozantinib 3 Standard of Care 3 Sirolimus 3 Ifosfamide 3 Bevacizumab 3 ulixertinib 2 tipifarnib 2 tazemetostat 2 olaparib 2 liposomal doxorubicin 2 larotrectinib 2 ivosidenib 2 fludarabine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03784014 2025-12-11

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Active not recruiting

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡